(Q28512774)

GOA release 2020-03-11

1 reference

Edward I. Ginns

1

1 reference

25 January 2017

Sally K.-K. Mak

2

1 reference

25 January 2017

Novie Ko

3

1 reference

25 January 2017

Juliane Karlgren

4

1 reference

25 January 2017

Schahram Akbarian

5

1 reference

25 January 2017

Vivian P. Chou

6

1 reference

25 January 2017

Yin Guo

7

1 reference

25 January 2017

Arlene Lim

8

1 reference

25 January 2017

Steven Samuelsson

9

1 reference

25 January 2017

Mary L. LaMarca

10

1 reference

25 January 2017

Jacqueline Vazquez-DeRose

11

1 reference

25 January 2017

Amy B. Manning-Boğ

Molecular Genetics and Metabolism

12

1 reference

25 January 2017

1 February 2014

1 reference

25 January 2017

1 reference

25 January 2017

111

1 reference

25 January 2017

2

1 reference

25 January 2017

152–162

1 reference

25 January 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Occurrence of Parkinson's syndrome in type I Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Parkinson's syndrome preceding clinical manifestation of Gaucher's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Gaucher disease and parkinsonism: a phenotypic and genotypic characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Gaucher disease associated with parkinsonism: four further case reports

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Gaucher's disease with Parkinson's disease: clinical and pathological aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Parkinsonism among Gaucher disease carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Glucocerebrosidase mutations in subjects with parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Increased incidence of Parkinson disease among relatives of patients with Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Glucocerebrosidase mutations are an important risk factor for Lewy body disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Gaucher disease: complexity in a "simple" disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Analysis of the glucocerebrosidase gene in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

The genetics of Parkinson disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Neuropathology provides clues to the pathophysiology of Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Horizontal saccadic palsy associated with gliosis of the brainstem midline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Brainstem pathology of infantile Gaucher's disease with only wave I and II of auditory brainstem response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Type 2 and type 3 Gaucher disease: a morphological and biochemical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Infantile Gaucher's Disease: Neuropathology, Acid Hydrolase Activities and Negative Staining Observations1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Functional brain imaging in glucocerebrosidase mutation carriers with and without parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Commentary on "Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease" by Zimran et al.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Differentiation of beta-glucocerebrosidase from beta-glucosidase in human tissues using sodium taurocholate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

A biochemical and ultrastructural evaluation of the type 2 Gaucher mouse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Brain glucocerebrosidase in Gaucher's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Evidence of oxidative stress in young and aged DJ-1-deficient mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Differential contribution of lipoxygenase isozymes to nigrostriatal vulnerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

α-Synuclein Overexpression Protects against Paraquat-Induced Neurodegeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Targeting of the Arpc3 actin nucleation factor by miR-29a/b regulates dendritic spine morphology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

MicroRNA regulation in experimental autoimmune encephalomyelitis in mice and marmosets resembles regulation in human multiple sclerosis lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Micromanaging vascular biology: tiny microRNAs play big band

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Glucosylceramide modulates endolysosomal pH in Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Lysosomal degradation of alpha-synuclein in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

SNAP-25 is present in a SNARE complex in adrenal chromaffin cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

SNAP receptors implicated in vesicle targeting and fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Synaptic vesicle membrane proteins interact to form a multimeric complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Neuroinflammation and synaptic loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

RETRACTED: Dose-dependent changes in neuroinflammatory and arachidonic acid cascade markers with synaptic marker loss in rat lipopolysaccharide infusion model of neuroinflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Neuroprotective effect of Pycnogenol® following traumatic brain injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Hippocampal drebrin loss in mild cognitive impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Loss of proteins regulating synaptic plasticity in normal aging of the human brain and in Alzheimer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Glucosylceramide synthase decrease in frontal cortex of Alzheimer brain correlates with abnormal increase in endogenous ceramides: consequences to morphology and viability on enzyme suppression in cultured primary neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and interleukin-1 beta on long term potentiation in rat dentate gyrus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Chronic brain inflammation results in cell loss in the entorhinal cortex and impaired LTP in perforant path-granule cell synapses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

LPS-induced neuroinflammatory effects do not recover with time.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Behavioral and ultrastructural changes induced by chronic neuroinflammation in young rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Roles of microRNAs beyond development--metabolism and neural plasticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

How do microRNAs regulate gene expression?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Origins and Mechanisms of miRNAs and siRNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

A microRNA array reveals extensive regulation of microRNAs during brain development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Thinking about RNA? MicroRNAs in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Repression of alpha-synuclein expression and toxicity by microRNA-7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

A role for miR-142-3p in colony-stimulating factor 1-induced monocyte differentiation into macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

TLR4 signaling induces the release of microparticles by tumor cells that regulate inflammatory cytokine IL-6 of macrophages via microRNA let-7b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

Astrocytic gliosis of vascular adventitia and arachnoid membrane in infantile Gaucher's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.12.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMGME.2013.12.003

1 reference

Consolidated OpenCitations Corpus – April 2017

release_clo7nr44nffnbagsqfjvfzxggq

3410850

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/clo7nr44nffnbagsqfjvfzxggq

mapped directly with Wikidata item

24 November 2022

based on heuristic

3410850

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference